Literature DB >> 24862586

Transient hyperckemia in the setting of neuromyelitis optica (NMO).

Rabia Malik1, Aaron Lewis, Bruce A C Cree, Julien Ratelade, Andrea Rossi, Alan S Verkman, Andrew W Bollen, Jeffrey W Ralph.   

Abstract

INTRODUCTION: Neuromyelitis optica (NMO) is characterized by inflammatory demyelinating lesions of the spinal cord and optic nerves from an autoimmune response against water channel aquaporin-4 (AQP4). We report 2 patients with transient hyperCKemia associated with NMO suggesting possible skeletal muscle damage.
METHODS: Patient 1 was a 72-year-old man who presented with muscle soreness and elevated serum creatine kinase (CK) preceding an initial attack of NMO. Patient 2 was a 25-year-old woman with an established diagnosis of NMO who presented with diffuse myalgias, proximal upper extremity weakness, and hyperCKemia. Muscle biopsies were obtained for histopathologic evaluation, protein gel electrophoresis, immunofluorescence, and complement staining.
RESULTS: In both patients the muscle showed only mild variation in fiber diameter. There were no inflammatory changes or muscle fiber necrosis, though there was reduced AQP4 expression and deposition of activated complement.
CONCLUSIONS: Complement-mediated sarcolemmal injury may lead to hyperCKemia in NMO.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  aquaporin 4; creatine kinase; hyperCKemia; immunofluorescence; neuromyelitis optica

Mesh:

Substances:

Year:  2014        PMID: 24862586      PMCID: PMC4306419          DOI: 10.1002/mus.24298

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Neuromyelitis optica preceded by hyperCKemia episode.

Authors:  N Suzuki; T Takahashi; M Aoki; T Misu; S Konohana; T Okumura; H Takahashi; S Kameya; K Yamaki; T Kumagai; K Fujihara; Y Itoyama
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

Review 2.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

3.  Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica.

Authors:  Julien Ratelade; Jeffrey L Bennett; A S Verkman
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

4.  Post-Golgi supramolecular assembly of aquaporin-4 in orthogonal arrays.

Authors:  Andrea Rossi; Florian Baumgart; Alfred N van Hoek; A S Verkman
Journal:  Traffic       Date:  2011-11-08       Impact factor: 6.215

Review 5.  Aquaporins in clinical medicine.

Authors:  A S Verkman
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

6.  Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.

Authors:  S R Hinson; S J Pittock; C F Lucchinetti; S F Roemer; J P Fryer; T J Kryzer; V A Lennon
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

7.  HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica.

Authors:  Shoko Deguchi; Kentaro Deguchi; Kota Sato; Taijun Yunoki; Yoshio Omote; Nobutoshi Morimoto; Tomoko Kurata; Masami Ikeda; Toshiyuki Takahashi; Masashi Aoki; Koji Abe
Journal:  Intern Med       Date:  2012-09-15       Impact factor: 1.271

8.  Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Authors:  Samira Saadoun; Patrick Waters; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Brain       Date:  2010-01-04       Impact factor: 13.501

9.  Aquaporin-4 expression is severely reduced in human sarcoglycanopathies and dysferlinopathies.

Authors:  Stefania Assereto; Mauro Mastrototaro; Silvia Stringara; Elisabetta Gazzerro; Paolo Broda; Grazia Paola Nicchia; Maria Svelto; Claudio Bruno; Vincenzo Nigro; M P Lisanti; Antonio Frigeri; Carlo Minetti
Journal:  Cell Cycle       Date:  2008-05-12       Impact factor: 4.534

10.  Altered aquaporin-4 expression in human muscular dystrophies: a common feature?

Authors:  Antonio Frigeri; Grazia Paola Nicchia; Silvia Repetto; Massimo Bado; Carlo Minetti; Maria Svelto
Journal:  FASEB J       Date:  2002-05-08       Impact factor: 5.191

View more
  13 in total

Review 1.  Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.

Authors:  Jeffrey L Bennett; Gregory P Owens
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

2.  Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.

Authors:  Tianjiao Duan; Lukmanee Tradtrantip; Puay-Wah Phuan; Jeffrey L Bennett; Alan S Verkman
Journal:  Neuropharmacology       Date:  2019-10-22       Impact factor: 5.250

3.  The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study.

Authors:  Helle H Nielsen; Hans C Beck; Lars P Kristensen; Mark Burton; Tunde Csepany; Magdolna Simo; Peter Dioszeghy; Tobias Sejbaek; Manuela Grebing; Niels H H Heegaard; Zsolt Illes
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

4.  Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G.

Authors:  Christian M Felix; Marc H Levin; Alan S Verkman
Journal:  J Neuroinflammation       Date:  2016-10-20       Impact factor: 8.322

5.  Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G.

Authors:  Xiaoming Yao; Alan S Verkman
Journal:  Acta Neuropathol Commun       Date:  2017-07-27       Impact factor: 7.801

6.  Muscle damage in patients with neuromyelitis optica spectrum disorder.

Authors:  Hong-Xi Chen; Qin Zhang; Zhi-Yun Lian; Ju Liu; Zi-Yan Shi; Xiao-Hui Miao; Hui-Ru Feng; Qin Du; Jing-Lu Xie; Shao-Li Yao; Hong-Yu Zhou
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-09-13

7.  The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica.

Authors:  Alan S Verkman; Xiaoming Yao; Alex J Smith
Journal:  J Cell Mol Med       Date:  2018-01-24       Impact factor: 5.310

8.  Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.

Authors:  Jin Myoung Seok; Misong Choi; Eun Bin Cho; Hye Lim Lee; Byoung Joon Kim; Kwang Ho Lee; Pamela Song; Eun Yeon Joo; Ju-Hong Min
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

9.  Multisystem involvement in neuromyelitis optica.

Authors:  Megan M Langille; Jay Desai
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

10.  Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica.

Authors:  Stefania Rosito; Grazia Paola Nicchia; Claudia Palazzo; Anna Lia; Cinzia Buccoliero; Francesco Pisani; Maria Svelto; Maria Trojano; Antonio Frigeri
Journal:  J Cell Mol Med       Date:  2017-10-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.